Does celecoxib reduce the incidence of symptomatic ulcers and ulcer complications compared to standard NSAIDs in patients with osteoarthritis and rheumatoid arthritis?
Celecoxib at supratherapeutic doses is associated with lower upper gastrointestinal toxicity compared to standard-dose NSAIDs, particularly in patients not taking aspirin.
In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages. The decrease in upper GI toxicity was strongest among patients not taking aspirin concomitantly. JAMA. 2000;284:1247-1255
Silverstein et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: